Platelet-derived growth factors analyzers SEB-C100


Platelet-derived growth factors analyzers SEB-C100

Short Description:

This product used to analyze platelet-derived growth factor, a specific protein marker in human urine, and qualitatively analyze the degree of coronary artery stenosis.

Product Detail

Product Tags

Product introduction

The Platelet Derived Growth Factor Analyzer is a testing and analyzing instrument based on a unique testing method pioneered by our company. The analyzer detects platelet-derived growth factor, a specific protein marker in human urine produced when coronary artery stenosis occurs. The analysis can be completed in a few minutes by using only 1ml of urine. The analyzer can determine whether the coronary arteries have stenosis and the degree of stenosis so as to provide reference for further examination. The detection and analysis method of platelet-derived growth factor analyzer is an original non-invasive detection method, which does not require injections and auxiliary drugs, eliminating the problem that people allergic to iodine-containing contrast agents are unable to undergo CT and other coronary artery angiography. The analyzer has the advantages of low testing cost, wide range of application, easy application, fast testing speed, etc., and is a new type of coronary artery stenosis early detection and screening instrument.

The analyzer has the following advantages:

1. Rapidity: Put the urine into the detection device and just wait a few minutes

2. Convenience: Testing is not only available in hospitals. They can also be done at medical check-up facilities, nursing homes or community welfare homes

3. Comfort: Only 1ml of urine is needed as a sample, no blood draws, no medication, no contrast injections, no worries about allergic reactions

4. Intelligence: Fully automated inspection, working on unattended

5. Easy einstallation: Small size, can be installed and used with half a table

6. Easy maintenance: Automatically monitors and displays consumable status for easy consumable replacement


Principle of the product

Raman spectroscopy utilizes light scattering to rapidly analyze molecular structure. This technique is based on the principle that when light irradiates a molecule, elastic collisions occur and a portion of the light scatters. The frequency of the scattered light is different from the frequency of the incident light, known as Raman scattering. The intensity of Raman scattering associates with the molecule's structure, allowing for analysis of both its intensity and frequency to determine the molecule's nature and structure precisely.

Due to weak Raman signal and frequent fluorescence interference, obtaining Raman spectra during actual detection can be challenging. Effective detection of the Raman signal is truly difficult. Therefore, the surface enhanced Raman spectroscopy can significantly enhance the intensity of Raman scattered light, addressing these issues. The technique's fundamental principle involves placing the substance to be detected on a specialized metal surface, such as silver or gold. so as to create a rough, nanometer-level surface, resulting in a surface-enhancement effect.

It was demonstrated that the Raman spectrum of the marker platelet-derived growth factor (PDGF-BB) featured a distinct peak at 1509 cm-1. Further, it was established that the presence of marker platelet-derived growth factor (PDGF-BB) in urine correlated with coronary artery stenosis.

By Using Raman spectroscopy and surface enhancement technology, the PDGF analyzer can measure the presence of PDGF-BB and its characteristic peaks' intensity in urine. This enables the determination of whether coronary arteries are stenotic and the degree of stenosis, thus providing a basis for clinical diagnosis.

Background of the product

In recent years, the prevalence of coronary heart disease has been gradually increasing due to changes in dietary and lifestyle habits, as well as the aging population. The mortality rate associated with coronary heart disease remains alarmingly high. According to the China Cardiovascular Health and Disease Report 2022, the mortality rate of coronary heart disease among urban Chinese residents will be 126.91/100,000 and 135.88/100,000 among rural residents in 2020. The figure has been on the rise since 2012 with a significant increase in rural areas. In 2016, it exceeded that of the urban level and continued to rise in 2020. Currently, coronary arteriography is the primary diagnostic method used in clinical settings to detect coronary heart disease. While referred to as the "gold standard" for coronary heart disease diagnosis, its invasiveness and high cost have led to the development of electrocardiography as a gradually evolving alternative diagnostic method. Although electrocardiogram (ECG) diagnosis is simple, convenient, and inexpensive, misdiagnoses and omissions of diagnoses can still occur, rendering it unreliable for clinical diagnosis of coronary heart disease. Therefore, the development of a non-invasive, highly sensitive, and reliable method for early and rapid detection of coronary heart disease is of great significance.

Surface-enhanced Raman spectroscopy (SERS) has found widespread application in the life sciences for detecting biomolecules at extremely low concentrations. For instance, Alula et al. were able to detect minute levels of creatinine in urine by using SERS spectroscopy with photo catalytically modified silver nanoparticles containing magnetic substances.

Similarly, Ma et al. employed magnetically induced aggregation of nanoparticles in SERS spectroscopy to reveal extremely low concentrations of deoxyribonucleic acid (DNA) in bacteria.

Platelet-derived growth factor-BB (PDGF-BB) plays a key role in atherosclerosis development through multiple mechanisms and has close ties to coronary heart disease. Enzyme-linked immunosorbent assay (ELISA) is the predominant method used in current PDGF-BB research for detecting this protein in the bloodstream. For instance, Yuran Zeng and colleagues determined the plasma concentration of PDGF-BB by using enzyme-linked immunosorbent assay and discerned that PDGF-BB contributes significantly to the pathogenesis of carotid atherosclerosis. In our study, we first analyzed the SERS spectra of various PDGF-BB aqueous solutions with extremely low concentrations, utilizing our 785 nm Raman spectroscopy platform. We discovered that the characteristic peaks with a Raman shift of 1509 cm-1 were assigned to the aqueous solution of PDGF-BB. Additionally, we found that these characteristic peaks were also associated with the aqueous solution of PDGF-BB.

Our company collaborated with university research teams to conduct SERS spectroscopy analysis on a total of 78 urine samples. These included 20 samples from patients who underwent PCI surgery, 40 samples from patients who did not undergo PCI surgery, and 18 samples from healthy individuals. We meticulously analyzed the urine SERS spectra by merging the Raman peaks with a Raman frequency shift of 1509cm-1, which is directly linked to PDGF-BB. The research revealed that the urine samples of patients who underwent PCI surgery had a detectable characteristic peak of 1509cm-1, while this peak was absent in urine samples of healthy individuals and most non-PCI patients. At the same time, when the hospital's clinical data of coronary angiography was combined, it was determined that this detection method aligns well with determining if there is a cardiovascular blockage exceeding 70%. Moreover, this method can diagnose with a sensitivity and specificity of 85% and 87% respectively, the degree of blockage greater than 70% in cases of coronary artery disease by identifying the characteristic peaks of Raman of 1509 cm-1. 5%, therefore, this approach is expected to become a crucial foundation for deciding if patients with coronary artery disease require PCI, furnishing highly beneficial insights for the early detection of suspected cases of coronary artery disease.

Given this background, our company has implemented the outcomes of our earlier research by launching the Platelet Derived Growth Factor Analyzer. This device will significantly transform the promotion and widespread utilization of early coronary heart disease detection. It will significantly contribute to the improvement of the coronary heart's health in China and worldwide.


[1] Huinan Yang, Chengxing Shen, Xiaoshu Cai et al. Noninvasive and prospective diagnosis of coronary heart disease with urine using surface-enhanced Raman spectroscopy [J]. Analyst, 2018, 143, 2235–2242.

Parameter sheets

model number SEB-C100
test item Intensity of platelet-derived growth factor characteristic peaks in urine
Test Methods automation
Language Chinese
Detection Principle Raman spectroscopy
communication interface Micro USB Port, Network Port, WiFi
repeatable Coefficient of variation of test results ≤ 1.0%
degree of accuracy The results align closely with the sample values of the corresponding standards.
stability Coefficient of variation ≤1.0% for the same sample within 8 hours of power-on
Recording method LCD display, FlashROM data storage
detection time Detection time for a single sample is less than 120 seconds
Working Power power adapter:AC 100V~240V, 50/60Hz
external dimensions 700mm(L)*560mm(W)*400mm(H)
weight About75kg
working environment operating temperature: 10℃~30℃; relative humidity: ≤90%; air pressure: 86kPa~106kPa
Transportation and storage environment operating temperature: -40℃~55℃; relative humidity: ≤95%; air pressure: 86kPa~106kPa

  • Previous:
  • Next:

  • Write your message here and send it to us

    related products